Literature DB >> 11122860

The changing prognosis of melanoma.

A C Buzaid1, C M Anderson.   

Abstract

Cutaneous melanoma is a significant and increasing clinical problem. Knowing accurately the prognosis in a given patient is critical for treatment decisions and for optimal patient education. In this article we discuss the most current information regarding prognostic factors in early-stage and advanced malignant melanoma. Tumor thickness and ulceration are the most important predictors for primary melanoma. Number of positive lymph nodes is the most powerful predictor for stage III patients, and sites of disease and lactase dehydrogenase levels are the most useful predictors in metastatic disease.

Entities:  

Mesh:

Year:  2000        PMID: 11122860     DOI: 10.1007/s11912-000-0025-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  31 in total

1.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

2.  Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

Authors:  U Keilholz; C Conradt; S S Legha; D Khayat; C Scheibenbogen; N Thatcher; S H Goey; M Gore; T Dorval; B Hancock; C J Punt; R Dummer; M F Avril; E B Bröcker; A Benhammouda; A M Eggermont; M Pritsch
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

3.  S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.

Authors:  M Deichmann; A Benner; M Bock; A Jäckel; K Uhl; V Waldmann; H Näher
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

4.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

5.  Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion.

Authors:  C M Sutherland; F J Mather; E T Krementz
Journal:  Surg Gynecol Obstet       Date:  1987-02

6.  The prognosis and treatment of true local cutaneous recurrent malignant melanoma.

Authors:  C D Brown; J A Zitelli
Journal:  Dermatol Surg       Date:  1995-04       Impact factor: 3.398

7.  Cutaneous melanoma: prognosis and treatment results worldwide.

Authors:  C M Balch
Journal:  Semin Surg Oncol       Date:  1992 Nov-Dec

8.  Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases.

Authors:  J A Carlson; G R Dickersin; A J Sober; R L Barnhill
Journal:  Cancer       Date:  1995-01-15       Impact factor: 6.860

9.  Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification.

Authors:  P Büttner; C Garbe; J Bertz; G Burg; B d'Hoedt; H Drepper; I Guggenmoos-Holzmann; W Lechner; A Lippold; C E Orfanos
Journal:  Cancer       Date:  1995-05-15       Impact factor: 6.860

10.  Excisional biopsy as the first therapeutic procedure versus primary wide excision of malignant melanoma.

Authors:  M Landthaler; O Braun-Falco; A Leitl; B Konz; D Hölzel
Journal:  Cancer       Date:  1989-10-15       Impact factor: 6.860

View more
  3 in total

1.  [Histology of malignant tumors caused by UV light].

Authors:  M Megahed
Journal:  Hautarzt       Date:  2012-10       Impact factor: 0.751

Review 2.  Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Authors:  Eleonore Fröhlich
Journal:  Cell Mol Life Sci       Date:  2010-08-05       Impact factor: 9.261

Review 3.  Staging and prognosis of cutaneous melanoma.

Authors:  Paxton V Dickson; Jeffrey E Gershenwald
Journal:  Surg Oncol Clin N Am       Date:  2011-01       Impact factor: 3.495

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.